Alfredo Addeo
University of Geneva
CancerInternal medicineOncologyLung cancerChemotherapyPerformance statusImmunotherapynon-small cell lung cancer (NSCLC)MEDLINEPembrolizumabGemcitabinePD-L1KRASTargeted therapyNon small cellIn patientImmune checkpoint inhibitorsCancer researchText miningMedicineCohort
137Publications
22H-index
1,011Citations
Publications 144
Newest
#1Daniele Frisone (Geneva College)H-Index: 1
#2Alex Friedlaender (Geneva College)H-Index: 16
Last. Alfredo Addeo (Geneva College)H-Index: 22
view all 3 authors...
PURPOSE OF REVIEW There has been a huge development in the assessment of malignancies through liquid biopsies last years, especially for NSCLC, where its use has become part of clinical practice in some settings. We aim to summarize current evidence about minimal residual disease and its use in lung cancer. RECENT FINDINGS Recent studies using ctDNA in NSCLC but also in other types of cancer found strong correlations between the presence of ctDNA and the risk of disease progression or death afte...
Source
#1Alfredo AddeoH-Index: 22
#2Alex FriedlaenderH-Index: 16
Last. Christian Rolfo (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 46
view all 8 authors...
Purpose of review null Cancer vaccines are one of the most extensively studied immunotherapy type in solid tumors. Despite favorable presuppositions, so far, the use of cancer vaccines has been associated with disappointing results. However, a new generation of vaccines has been developed, promising to revolutionize the immunotherapy field. null Recent findings null In this review, we aim to highlight the advances in cancer vaccines and the remaining hurdles to overcome. Cancer vaccination has e...
Source
#2Alfredo AddeoH-Index: 22
Source
#1Umberto Malapelle (University of Naples Federico II)H-Index: 31
#2Pasquale Pisapia (University of Naples Federico II)H-Index: 20
Last. Christian Rolfo (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 46
view all 21 authors...
Introduction null : In the current era of personalized medicine, liquid biopsy has acquired a relevant importance in patient management of advanced stage non-small cell lung cancer (NSCLC). As a matter of fact, liquid biopsy may supplant the problem of inadequate tissue for molecular testing. The term "liquid biopsy" refers to a number of different biological fluids, but is most clearly associated with plasma-related platforms. It must be taken into account that pre-analytical processing and the...
Source
#1Alex Friedlaender (Geneva College)H-Index: 16
#2Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Last. Alfredo Addeo (Geneva College)H-Index: 22
view all 7 authors...
Source
#1Alex Friedlaender (Geneva College)H-Index: 16
#2Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Last. Alfredo Addeo (Geneva College)H-Index: 22
view all 7 authors...
Protein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung, breast and gastroesophageal cancers, and are of relevance for the treatment of various other malignancies (particularly colorectal cancer). Classic activating EGFR exon 19 deletions and exon 21 mutations, and HER2 amplification and/or overexpression, are predictive of response to matched molecularly targeted therapies, trans...
Source
#1Alfredo AddeoH-Index: 22
Source
#1André Manuel da Silva Lopes (UNIL: University of Lausanne)
#2Sara Colomer-Lahiguera (UNIL: University of Lausanne)H-Index: 2
Last. Bart NeynsH-Index: 62
view all 15 authors...
BACKGROUND Immune-related adverse events (IrAEs) associated with the use of immune checkpoint inhibitors (ICIs) may not be fully covered by existing measures like the PRO-CTCAE™. Selecting PRO-CTCAE™ items for monitoring symptomatic adverse events is hindered by the heterogeneity and complexity of IrAEs, and no standardised selection process exists. We aimed to reach expert consensus on the PRO-CTCAE™ symptom terms relevant for cancer patients receiving ICIs and to gather preliminary expert opin...
Source
Source
#1A.M.D.S. Lopes (CHUV: University Hospital of Lausanne)
#2S. Colomer-Lahiguera (CHUV: University Hospital of Lausanne)
Last. Bart Neyns (Vrije Universiteit Brussel)H-Index: 62
view all 15 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.